MannKind Corporation (MNKD)
NASDAQ:MNKD
Want to see MNKD full AI Analyst Report?
MNKD Stock Chart & Stats
$2.84
-$0.05(-0.80%)
At close: 4:00 PM EST
$2.84
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$2.23 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)6.60M
Market Cap
$1.10B
Enterprise Value$1.55B
Total Cash (Recent Filing)$133.86M
Total Debt (Recent Filing)$436.67M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 12, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding308,950,160
10 Day Avg. Volume6,334,613
30 Day Avg. Volume6,604,720
Financial Highlights & Ratios
PEG Ratio-3.69
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue4.29
Enterprise Value/Gross Profit5.65
Enterprise Value/Ebitda54.34
Forecast
1Y Price Target
$8.15Price Target Upside186.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$461.85M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & High Gross MarginSustained top-line expansion with roughly 79% TTM gross margin indicates the business model captures significant value from sales. High gross margins provide durable profitability leverage as revenues scale, supporting reinvestment in commercial expansion and pipeline programs over the next 2-6 months.
Improved Cash GenerationConversion to positive operating and free cash flow across recent years shows improving cash generation and operational discipline. Positive FCF supports funding launches, milestone-driven R&D, and strategic obligations without immediate dependence on external financing, bolstering financial durability.
Regulatory Expansion & Partner ManufacturingPediatric FDA approval materially expands the Afrezza addressable market and completes a regulatory milestone, supporting long-term demand. Meanwhile, a contractual Tyvaso manufacturing agreement provides predictable partner-derived revenue, diversifying and stabilizing the company's commercial base.
Bears Say
Negative Shareholders' EquityPersistent negative equity reduces financial flexibility and constrains the company's ability to absorb shocks or fund aggressive growth without dilutive financing. Over 2-6 months this structural capital weakness could limit strategic optionality and increase financing costs for new investments.
Earnings Volatility & Return To LossesReversal from prior profitability to recent GAAP losses evidences earnings volatility tied to integration and investment. Such swings make forward earnings less predictable, complicate cash planning, and increase execution risk as the company funds launches and pipeline work over the coming months.
Access Hurdles For FURO6High prior-authorization rates materially constrain durable prescription growth and create dependency on payer negotiations. Over the medium term this can limit adoption velocity, depress realized revenue per patient, and require sustained commercial effort to overcome reimbursement barriers.
MannKind News
MNKD FAQ
What was MannKind Corporation’s price range in the past 12 months?
MannKind Corporation lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is MannKind Corporation’s market cap?
MannKind Corporation’s market cap is $1.10B.
When is MannKind Corporation’s upcoming earnings report date?
MannKind Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 63 days.
How were MannKind Corporation’s earnings last quarter?
MannKind Corporation released its earnings results on May 06, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.05.
Is MannKind Corporation overvalued?
According to Wall Street analysts MannKind Corporation’s price is currently Undervalued.
Does MannKind Corporation pay dividends?
MannKind Corporation does not currently pay dividends.
What is MannKind Corporation’s EPS estimate?
MannKind Corporation’s EPS estimate is >-0.01.
How many shares outstanding does MannKind Corporation have?
MannKind Corporation has 308,950,160 shares outstanding.
What happened to MannKind Corporation’s price movement after its last earnings report?
MannKind Corporation reported an EPS of -$0.05 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -0.281%.
Which hedge fund is a major shareholder of MannKind Corporation?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.15 (186.97% Upside)
$8.15 (186.97% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 853.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $259.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.30%
12-Months-Change
Fundamentals
Return on Equity
45.59%
Trailing 12-Months
Asset Growth
81.50%
Trailing 12-Months
Company Description
MannKind Corporation
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$8.15
▲(186.97% Upside)
Technical Analysis
Ownership Overview
2.61% Insiders
10.74% Mutual Funds
9.65% Other Institutional Investors
61.03% Public Companies and
Individual Investors